HR 3546
Prescription Drug Price Relief Act of 2025
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:04 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
The Prescription Drug Price Relief Act of 2025 aims to lower prescription drug costs by addressing what the bill considers excessive pricing by brand-name drug manufacturers. It establishes a process for the Department of Health and Human Services (HHS) to review drug prices annually and void government-granted monopolies if prices are deemed excessive. The bill also promotes the availability of generic and biosimilar drugs by expediting their review and establishing a system for licensing brand-name drugs, along with requiring manufacturers to report detailed financial information.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.